

11 August 2020

ASX ANNOUNCEMENT

ImpediMed Announces Appointment of Chief Financial Officer

Brisbane, Australia – ImpediMed Limited (ASX: IPD) a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), announces the promotion of Timothy Cruickshank to Chief Financial Officer. Mr Cruickshank was appointed to the role of Executive Vice President of Finance and interim CFO in March of this year. Mr Cruickshank served as Vice President of Finance for the past four years and since taking responsibilities of CFO activities has reported into Richard Carreon, Managing Director and CEO.

“During his tenure, Tim has been a key leader within finance as we’ve transformed the Company through an ever-evolving environment. Tim took on the role of interim CFO during the onset of the global pandemic and successfully supported the company through this very challenging period. He has been instrumental in negotiating our national contracts and has worked diligently with the executive team on numerous growth initiatives. Tim is a great addition to the executive management team and has their full support as well as the board. We look forward to his continued contributions to the future success of ImpediMed.” commented Mr Carreon.

Mr Cruickshank joined the company in 2008, making increasing contributions to the corporate finance, treasury, strategy, investor relations, tax, accounting, external audit and risk management functions. Tim brings to the role an intricate knowledge of the Company’s corporate strategy, SaaS modeling, and financial procedures and controls.

“I’ve had the opportunity over the past decade to witness the transformation of our Company’s technology into the connected digital health platform it is today, while also recently helping the Company navigate through a unique and complex quarter. I am very excited to help lead our Company through our next exciting stage of growth, as we rapidly expand our SaaS model and invest in critical strategic initiatives, all while adhering to strong financial discipline,” said Mr Cruickshank.

Mr Cruickshank holds a Master of Financial and Accounting Management from Keller Graduate School of Management in Queens, New York and a Bachelor of Science, Accounting from Syracuse University in Syracuse, New York.

Contact Details

Investor Relations Contact:

Mike Bassett, ImpediMed

T : +61 407 431 432

E: mbassett@impedimed.com

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@we-worldwide.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.